×
About 4,053 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  1,148 results

Adrenal Crisis
http://emedicine.medscape.com/article/116716-overview

Jan 13th, 2022 - Practice Essentials Do not confuse acute adrenal crisis with Addison disease. In 1855, Thomas Addison described a syndrome of long-term adrenal insufficiency that develops over months to years, with weakness, fatigue, anorexia, weight loss, and hy...

A mathematical model of the rat kidney IV: whole-kidney response to hyperkalemia.
https://doi.org/10.1152/ajprenal.00413.2021
American Journal of Physiology. Renal Physiology; Weinstein AM

Jan 11th, 2022 - The renal response to acute hyperkalemia is mediated by increased K secretion within connecting tubule (CNT), flux that is modulated by tubular effects (e.g. aldosterone) in conjunction with increased luminal flow. There is ample evidence that per...

Familial hyperkalemic hypertension: hyperkalemia not hypertension defines dominant KLHL...
https://doi.org/10.1007/s40620-021-01217-5 10.1038/nature10814 10.1146/annurev-physiol-021115-105431 10.1681/ASN.2017060660 10.1016/j.kint.2018.05.001 10.1073/pnas.1421441112 10.1093/ndt/gfz173
Journal of Nephrology; Sambharia M, Gattineni J et. al.

Jan 10th, 2022 - Familial hyperkalemic hypertension: hyperkalemia not hypertension defines dominant KLHL3 disease and may permit earlier recognition and tailored therapy.|2022|Sambharia M,Gattineni J,Noureddine L,Mansilla MA,Thomas CP,|

Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in H...
https://doi.org/10.1002/cpdd.1055
Clinical Pharmacology in Drug Development; Cheung T, Sun F et. al.

Jan 9th, 2022 - Sodium zirconium cyclosilicate (SZC) is an effective potassium binder for patients with hyperkalemia. This single-center, open-label, phase I study (NCT03283267) characterized the pharmacodynamics and safety of SZC in Chinese individuals. Twenty-t...

Potassium and fiber: a controversial couple in the nutritional management of children w...
https://doi.org/10.1007/s00467-021-05365-5
Pediatric Nephrology (Berlin, Germany); El Amouri A, Delva K et. al.

Jan 8th, 2022 - Fruit and vegetable intake is commonly discouraged in children with chronic kidney disease (CKD) to avoid hyperkalemia. However, direct evidence in support of this widespread practice is lacking. Furthermore, the resultant restricted fiber exposur...

see more →

Guidelines  1 results

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

see more →

Drugs  144 results see all →

Clinicaltrials.gov  51 results

CRRT Timing in Sepsis-associated AKI in ICU
https://clinicaltrials.gov/ct2/show/NCT03175328

Dec 22nd, 2021 - In our study, 460 patients with SAKI at KDIGO 2 from multicenter in China will be recruited. And then the patients will be divided into early group and delayed group randomly. In the early group, CRRT was started immediately after randomization. I...

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
https://clinicaltrials.gov/ct2/show/NCT04676646

Dec 14th, 2021 - REALIZE-K is a Phase 4, multinational, multicenter, double-blind, placebo-controlled, randomized-withdrawal, parallel-group study that includes the following 3 phases: screening, 4-6 week open-label run-in phase where sodium zirconium cyclosilicat...

Occurrence of Dyskalemia With Treatment for Hypertension
https://clinicaltrials.gov/ct2/show/NCT05155436

Dec 13th, 2021 - Hypertension affects an estimated 1.04 billion people in low- and middle-income countries, with an estimated increase in prevalence of 7.7% between 2000 and 2010.1 Hypertension treatment and control may lower the risk of cardiovascular disease and...

Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans
https://clinicaltrials.gov/ct2/show/NCT05145309

Dec 6th, 2021 - This is a double blind, randomized crossover trial comprising two phases: Placebo Phase (microcrystalline cellulose in water) and KMgCit Phase (KMgCit powder in water) to investigate the use of KMgCit in lowering blood pressure and reducing arteri...

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
https://clinicaltrials.gov/ct2/show/NCT05136664

Nov 29th, 2021 - In Part A, participants who meet all eligibility criteria will initiate patiromer at an oral dose of 8.4 g (1 packet/day). The dose will be adjusted based on the serum potassium (sK+) levels. After the completion of part A, all the participants wh...

see more →

News  277 results

Fast Five Quiz: Workup for Hyperkalemia
https://www.medscape.com/viewarticle/963569

Dec 9th, 2021 - Hyperkalemia is characterized by serum or plasma potassium levels above the upper limits of normal, typically greater than 5.0-5.5 mEq/L. Although patients with mild hyperkalemia are often asymptomatic, high levels of potassium may cause life-thre...

Fast Five Quiz: Hyperkalemia Signs and Symptoms
https://www.medscape.com/viewarticle/943636

Dec 7th, 2021 - Hyperkalemia refers to an elevation in potassium concentration, usually defined as a serum potassium concentration greater than approximately 5.0-5.5 mEq/L in adults. Prevalence estimates range from 1.5% in the general population, 5.6% in patients...

Fast Five Quiz: Can You Identify and Treat Hyperkalemia?
https://www.medscape.com/viewarticle/849260

Dec 3rd, 2021 - Hyperkalemia — serum potassium greater than approximately 5.0-5.5 mEq/L in adults — is associated with kidney disease, heart failure, a diet high in potassium, and drugs that impair renal potassium excretion. It can also appear in infants or child...

Novel and Alternative Strategies for Management of Panitumumab-Induced Hypomagnesemia
https://www.mdedge.com/fedprac/avaho/article/246950/oncology/novel-and-alternative-strategies-management-panitumumab
Katie Rogers, PharmD candidate ([email protected]), Sierra Vig, PharmD, BCOP, BCPS et. al.

Oct 1st, 2021 - Background Panitumumab is an epidermal growth factor receptor (EGFR) inhibiting monoclonal antibody approved for the treatment of RAS wild-type metastatic colorectal cancer (mCRC), which has an incidence of hypomagnesemia of approximately 35%. Gra.

Will the Positive Findings From the SSaSS Trial on Salt Substitution Silence the Salt Skeptics?
https://www.medscape.com/viewarticle/957510

Sep 2nd, 2021 - This transcript has been edited for clarity. John M. Mandrola, MD: Hey everyone, this is John Mandrola from the heart.org | Medscape Cardiology, and I'm delighted to be with Professor Bruce Neal, who is professor of medicine at University of New S...

see more →